A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2023; you can also visit the original URL.
The file type is application/pdf.
1202 Voclosporin for Lupus Nephritis: Results of the Two-year AURORA 2 Continuation Study
2022
2022 Lupus 21st Century Encore
unpublished
Preserved Fulltext
Figure 1 LS Mean eGFR over Time. Analysis of AURORA 2 patients includes data from pre-treatment baseline of AURORA 1, 12 months in AURORA 1 and up to 25 months in AURORA 2 (including 4-week post-treatment visit). Renal function assessed with corrected eGFR (Chronic Kidney Disease Epidemiology Collaboration equation) using a prespecified ceiling of 90 mL/min/1.73 m2. Cl, confidence interval; eGFR, estimated glomerular filtration rate; FUP, follow-up visit (4-week post-treatment visit); LS Mean, least squares mean.
doi:10.1136/lupus-2022-lupus21century.84
fatcat:is2r5ck7djfvpdazysfznrnt7i